Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629443
Status:
COMPLETED
Last Update Posted:
2024-06-06
First Post:
2020-11-03
Brief Title:
Phase III Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
Sponsor:
Institut de Recherches Internationales Servier
Organization:
Servier
Study Overview
Official Title:
Phase III International Multicentre Open-label Non-randomised Non-comparative Study Evaluating the Safety Tolerability and Clinical Activity of Intravenously Administered S64315 a Selective Mcl-1 Inhibitor in Combination With Azacitidine in Patients With Acute Myeloid Leukaemia AML
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability and clinical activity of the combination S64315 with azacitidine in patients with acute myeloid leukaemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-004896-38 | EUDRACT_NUMBER | None | None |